Mogamulizumab (KW-0761) is a defucosylated humanized recombinantanti-CCR4monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL)^[1][2][3].

Mogamulizumab (10 μg/mL, 24 h) induces ADCC activity against CCR4-positive cell lines (SNT8, SNT16, SNK6, and KAI3) in the presence of PBMCs^[2].
Mogamulizumab (10 μg/mL, 3 days) reduces the human T-lymphotropic virus type 1 (HTLV-1) proviral load and inhibits spontaneous proliferation in PBMCs from patients with HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP)^[3].
Mogamulizumab (1 μg/mL, 5 days) eliminates the CD4⁺CCR4⁺T cells in cultured PBMCs from patients with HAM/TSP^[3].

Mogamulizumab (1 mg/kg, i.p., twice per week for 4 weeks) together with PBMC transplantation inhibits the growth of EBV-positive NK-cell lymphomas in a murine xenograft model^[2].
Mogamulizumab (0.1 mg/kg, i.v., every other day) together with canine PBMCs (every fourth day)), inhibits tumor growth in canine bladder cancer-engrafted mouse model^[4].
Mogamulizumab (0.01-1 mg/kg, i.v.) reduces circulating CD4⁺CCR4⁺T cells, with no adverse effect in dogs^[4].

1159266-37-1

Please store the product under the recommended conditions in the Certificate of Analysis.